| Tag |
First Indicator |
Second Indicator |
Subfields |
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
in00005772874 |
| 005 |
20260327175527.9 |
| 006 |
m o d |
| 007 |
cr cnu|||unuuu |
| 008 |
240131s2024 ne a ob 001 0 eng d |
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d N$T
|d OCLCO
|d OPELS
|d YDX
|d OCLCL
|d SFB
|
| 020 |
|
|
|a 9780128118153
|q (electronic bk.)
|
| 020 |
|
|
|a 0128118156
|q (electronic bk.)
|
| 020 |
|
|
|z 9780128117644
|
| 035 |
|
|
|a (OCoLC)1419466674
|
| 050 |
|
4 |
|a RM316
|
| 082 |
0 |
4 |
|a 615.7/8
|2 23/eng/20240206
|
| 049 |
|
|
|a TXAM
|
| 100 |
1 |
|
|a Gerona, Roy,
|e author.
|
| 245 |
1 |
0 |
|a Designer drugs :
|b chemistry, analysis, regulation, toxicology, epidemiology & legislation of new psychoactive substances /
|c Roy Gerona.
|
| 264 |
|
1 |
|a Amsterdam, Netherlands :
|b Elsevier,
|c [2024].
|
| 300 |
|
|
|a 1 online resource :
|b illustrations.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 520 |
|
|
|a A title in the Emerging Issues in Analytical Chemistry series, Designer Drugs: Chemistry, Analysis, Regulation, Toxicology, Epidemiology & Legislation of New Psychoactive Substances presents both an overview and a guide to techniques for designer drug analysis. Proliferation of the synthesis and use of designer drugs is a serious public health problem with social, economic, and legal implications. Whether abuse is studied at the population level or the individual level, researchers need both background and highly detailed technical information on specific drugs and drug classes in order to combat the proliferation and highly damaging consequences of these substances. Author Roy Gerona provides a comprehensive discussion that emphasizes the potential threat to society, presents the ongoing challenges confronting the various laboratory approaches to detection and identification of new chemical entities, and informs the development of improved analytical solutions for use in legislation, law enforcement, and treatment. Designer Drugs: Chemistry, Analysis, Regulation, Toxicology, Epidemiology & Legislation of New Psychoactive Substances offers an introduction to the field and a source of information on specific drugs, drug effects, and analytical tools to a wide audience for anyone studying or engaging in designer drug analysis. Analytical and medical chemists, pharmacologist, toxicologists, and students, researchers, and policy makers in the fields of drug abuse, medicine, public health, and forensics will greatly benefit from this essential text.Summarizes available literature and evaluates the strengths and weaknesses of analytical methods for detecting and identifying designer drugsDirects the reader to sources of further reading at the conclusion of each chapterEmphasizes the potential threat to societyPresents ongoing challenges confronting various laboratory approaches to detection and identification of new chemical entities
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (EBSCO, viewed February 6, 2024).
|
| 505 |
0 |
|
|a Front Cover -- DESIGNER DRUGS -- DESIGNER DRUGSCHEMISTRY, ANALYSIS, REGULATION, TOXICOLOGY, EPIDEMIOLOGY & -- LEGISLATION OF NEW PSYCHOACTIVE SUBSTANCESROY GER ... -- Copyright -- Dedication -- Contents -- Foreword -- Preface -- Acknowledgments -- 1 -- NPS origins and use -- Definition -- Origins -- The 21st-century resurgence -- Synthetic cannabinoids -- Synthetic cathinones -- New synthetic opioids -- Designer benzodiazepines -- Other classes -- Production, marketing, and supply -- Patterns of use, effects, and toxicity -- Detection and identification of use -- Control and regulation -- References -- 2 -- NPS chemistry, classification, and metabolism -- Current classification systems -- Pharmacological classification -- Legal classification -- Classification based on origin -- Chemical classification -- A proposed NPS classification -- Metabolic transformations of common NPS classes -- Amphetamines and phenethylamines -- Synthetic cathinones -- Synthetic cannabinoids -- New synthetic opioids -- Designer benzodiazepines -- References -- 3 -- NPS pharmacology and toxicology -- Acute toxicity and long-term effects -- Synthetic cannabinoids -- Synthetic cathinones -- Amphetamines and phenethylamines -- Other stimulants and psychedelics -- Aminoindanes -- Benzofurans -- Tryptamines -- Piperazines -- Piperidines -- Dissociatives -- New synthetic opioids -- Designer benzodiazepines -- References -- 4 -- NPS analysis -- Workflow -- Chain of custody and documentation -- Sample matrices -- Urine -- Blood -- Hair -- Oral fluid -- Dried blood spot -- Others -- Sample preparation strategies -- Protein precipitation -- Liquid-liquid extraction -- Solid-phase extraction -- Presumptive and confirmatory analyses -- References -- 5 -- NPS screening -- Screening platforms -- Colorimetric assays (spot tests) -- Immunoassays -- Synthetic cannabinoids.
|
| 505 |
8 |
|
|a Stimulants, psychedelics, and dissociatives -- New synthetic opioids and designer benzodiazepines -- References -- 6 -- NPS confirmation using targeted analysis -- Confirmatory analysis -- Liquid chromatography-tandem mass spectrometry -- Liquid chromatography -- Mass spectrometry -- Ion source -- Mass analyzer -- Mass detector -- Drug identification and quantitation using LC-MS/MS -- Use in NPS analysis -- Broad-spectrum NPS analysis -- Synthetic cannabinoids -- Stimulants, psychedelics, and dissociatives -- New synthetic opioids and designer benzodiazepines -- References -- 7 -- NPS analysis using high-resolution mass spectrometry -- HRMS platforms and role in NPS analysis -- Instrumental analysis techniques -- Data acquisition strategies -- Data-dependent acquisition -- Data-independent acquisition -- Data processing techniques -- Targeted analysis -- Suspect screening -- Nontargeted analysis -- Laboratory application of LC-HRMS analysis -- Use in NPS analysis -- LC-TOF/MS -- LC-QTOF/MS -- Data-dependent acquisition strategies -- Data-independent acquisition strategies -- Advantages and limitations of LC-HRMS -- References -- 8 -- NPS surveillance and epidemiology -- Sampling strategies -- Surveillance systems -- Global surveillance and UNODC -- Europe -- The Early Warning System -- Three periods of the EWS -- 1997 to 2007 -- 2008 to 2015 -- 2016 to 2022 -- STRIDA -- Euro-DEN -- The United States -- Poison control center reports -- National Forensic Laboratory Information System -- NFLIS-drug reports -- Survey of toxicology laboratories -- Multidisciplinary NPS testing -- Prophetic synthetic cannabinoids library -- DEA TOX -- Other surveillance systems -- Changing motivations and patterns of use -- References -- 9 -- NPS regulation and legislation -- Challenges -- Control of psychoactive drugs: International drug laws.
|
| 505 |
8 |
|
|a Control of psychoactive drugs: Scheduling in the United States -- The European framework for NPS control -- Scheduling strategies in Asia and Oceania -- Generic legislation and blanket ban -- References -- Index -- Back Cover.
|
| 650 |
|
0 |
|a Designer drugs.
|
| 650 |
|
2 |
|a Designer Drugs
|
| 650 |
|
6 |
|a Drogues de confection.
|
| 655 |
|
7 |
|a Electronic books.
|2 local
|
| 710 |
2 |
|
|a ScienceDirect (Online service)
|
| 856 |
4 |
0 |
|u http://proxy.library.tamu.edu/login?url=https://www.sciencedirect.com/science/book/9780128117644
|z Connect to the full text of this electronic book
|t 0
|
| 955 |
|
|
|a Elsevier ScienceDirect 2026-2027
|
| 994 |
|
|
|a 92
|b TXA
|
| 999 |
f |
f |
|i f8d12194-1225-45eb-8422-8e96deb169a2
|s 1239aa6a-c088-46ae-95c7-d31aa0680965
|t 0
|
| 952 |
f |
f |
|a Texas A&M University
|b College Station
|c Electronic Resources
|s www_evans
|d Available Online
|t 0
|e RM316
|h Library of Congress classification
|
| 998 |
f |
f |
|a RM316
|t 0
|l Available Online
|